Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2024 | $96.00 | Neutral | Cantor Fitzgerald |
| 8/2/2024 | $85.00 → $105.00 | Buy | Lake Street |
| 5/31/2024 | $100.00 | Buy | ROTH MKM |
| 4/26/2024 | $59.00 → $75.00 | Hold → Buy | Stifel |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/23/2023 | $60.00 | Mkt Outperform | JMP Securities |
| 9/6/2023 | $70.00 | Outperform | Oppenheimer |
| 8/3/2023 | $63.00 → $67.00 | Buy → Hold | Jefferies |
SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and
BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that management will be participating in three upcoming investor conferences in November. UBS Global Healthcare Conference Wednesday, November 13, 2024 Terranea Resort, Rancho Palos Verdes, CA David Roberts, President, will present at 7:15 AM PT Stifel's 2024 Healthcare Conference Tuesday, November 19, 2024 Lotte NY Palace Hotel, New York City David Roberts, President, will present at 1:50 PM ET Wolfe Research Healthcare Conference 2024 Wednesday, November 20, 2024 Wolfe Research HQ, New York City David Roberts, President, wi
BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results Sales $54.8mm, +16% (+16% organic) vs. Q3 2023Gross margin 67.8%, +280 bpsOp. income $13.1mm, +43%Op. margin 24%Earnings per diluted share $0.49, +46%Cash up $10.8mm sequentially to $123.9mm Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sales growth. APAC sales increased 24%, EMEA 22% and the Americas 12%. The gross margin increased to 67.8% (vs. 65.0% in Q3 2023), driven by price increases and manufacturing efficiencie
BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and
BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results Sales $54.8mm, +16% (+16% organic) vs. Q3 2023Gross margin 67.8%, +280 bpsOp. income $13.1mm, +43%Op. margin 24%Earnings per diluted share $0.49, +46%Cash up $10.8mm sequentially to $123.9mm Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sales growth. APAC sales increased 24%, EMEA 22% and the Americas 12%. The gross margin increased to 67.8% (vs. 65.0% in Q3 2023), driven by price increases and manufacturing efficiencie
BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and
BURLINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q2 2024 Financial Results Sales $55.8mm, +11% (+12% organic) vs. Q2 2023 Gross margin 68.9%, +490 bpsOp. income $14.4mm, +52%Op. margin 26%Net income $11.8mm, +46%Earnings per diluted share $0.52, +44%Cash up $4.8mm sequentially to $113.1mm Allografts (+30%), bovine patches (+12%) and carotid shunts (+22%) led Q2 sales growth. APAC sales increased 20%, EMEA 13% and the Americas 10%. The gross margin increased to 68.9% (vs. 64.0% in Q2 2023), driven by manufac
Cantor Fitzgerald initiated coverage of Lemaitre Vascular with a rating of Neutral and set a new price target of $96.00
Lake Street resumed coverage of Lemaitre Vascular with a rating of Buy and set a new price target of $105.00 from $85.00 previously
ROTH MKM resumed coverage of Lemaitre Vascular with a rating of Buy and set a new price target of $100.00
LeMaitre Vascular (NASDAQ:LMAT) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.75, along with a high estimate of $100.00 and a low estimate of $75.00. This current averag
Roth MKM analyst Jason Wittes reinstates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and announces $100 price target.
Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $69 to $79.